抗生素治疗对部分宫颈机能不全伴羊膜腔内感染/炎症患者有效的证据
本研究纳入22例孕16.0至27.9周、无痛性宫颈扩张>1 cm且羊膜腔感染/炎症的 singleton 孕妇,给予头孢曲松、克拉霉素和甲硝唑治疗。75%(9/12)复查羊水穿刺者炎症或感染消退,59%(13/22)治疗成功,约60%病例获得治疗成功。
要点
- 22例宫颈机能不全伴羊膜腔感染/炎症患者接受头孢曲松、克拉霉素和甲硝唑治疗。
- 12例复查羊水穿刺者中75%(9/12)羊膜腔炎症或感染消退。
- 治疗成功(炎症消退或孕≥34周分娩)见于59%(13/22)病例。
核心结论
- 在宫颈机能不全伴羊膜腔感染/炎症患者中,使用头孢曲松、克拉霉素和甲硝唑后,75%患者羊膜腔炎症过程或感染消退,约60%病例治疗成功。
研究设计与样本
- 研究人群为22名符合以下标准的孕妇:单胎妊娠;孕16.0至27.9周无痛性宫颈扩张>1 cm;胎膜完整且无子宫收缩;行经腹羊膜腔穿刺评估羊膜腔微生物和炎症状态;存在羊膜腔感染/炎症;接受抗生素治疗(方案为头孢曲松、克拉霉素和甲硝唑)。
主要发现
- 22例中3例(14%)羊水检出微生物。
- 22例中6例(27%)在羊膜腔穿刺后1周内分娩,其余16例(73%)在诊断操作后超过1周分娩。
- 16例中12例复查羊膜腔穿刺,其中75%(9/12)通过复查时羊水分析有客观证据表明羊膜腔炎症或感染消退。
- 4例未复查羊膜腔穿刺者均孕≥34周分娩,其中2例足月分娩;治疗成功见于59%(13/22)病例。
关键数值与推荐
- 羊膜腔感染定义为羊水微生物培养阳性或解脲脲原体(Ureaplasma spp.)聚合酶链反应阳性。
- 羊膜腔炎症疑似标准为羊水白细胞计数升高(≥19 cells/mm3)或金属蛋白酶-8快速试验阳性(灵敏度10 ng/mL)。
- 羊膜腔炎症诊断「金标准」为酶联免疫吸附试验测定白细胞介素-6浓度升高(>2.6 ng/mL)。
- 治疗成功定义为羊膜腔感染/炎症消退或孕≥34周分娩。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cervical insufficiency is a risk factor for spontaneous midtrimester abortion or early preterm birth. Intra-amniotic infection has been reported in 8-52% of such patients and intra-amniotic inflammation in 81%. Some professional organizations have recommended perioperative antibiotic treatment when emergency cervical cerclage is performed. The use of prophylactic antibiotics is predicated largely on the basis that they reduce the rate of complications during the course of vaginal surgery. However, it is possible that antibiotic administration can also eradicate intra-amniotic infection/inflammation and improve pregnancy outcome. OBJECTIVE: To describe the outcome of antibiotic treatment in patients with cervical insufficiency and intra-amniotic infection/inflammation. STUDY DESIGN: The study population consisted of 22 women who met the following criteria: (1) singleton pregnancy; (2) painless cervical dilatation of >1 cm between 16.0 and 27.9 weeks of gestation; (3) intact membranes and absence of uterine contractions; (4) transabdominal amniocentesis performed for the evaluation of the microbiologic and inflammatory status of the amniotic cavity; (5) presence of intra-amniotic infection/inflammation; and (6) antibiotic treatment (regimen consisted of ceftriaxone, clarithromycin, and metronidazole). Amniotic fluid was cultured for aerobic and anaerobic bacteria and genital mycoplasmas, and polymerase chain reaction for Ureaplasma spp. was performed. Intra-amniotic infection was defined as a positive amniotic fluid culture for microorganisms or a positive polymerase chain reaction for Ureaplasma spp., and intra-amniotic inflammation was suspected when there was an elevated amniotic fluid white blood cell count (≥19 cells/mm3) or a positive rapid test for metalloproteinase-8 (sensitivity 10 ng/mL). For the purpose of this study, the "gold standard" for diagnosis of intra-amniotic inflammation was an elevated interleukin-6 concentration (>2.6 ng/mL) using an enzyme-linked immunosorbent assay. The results of amniotic fluid interleukin-6 were not available to managing clinicians. Follow-up amniocentesis was routinely offered to monitor the microbiologic and inflammatory status of the amniotic cavity and fetal lung maturity. Treatment success was defined as resolution of intra-amniotic infection/inflammation or delivery ≥34 weeks of gestation. RESULTS: Of 22 patients with cervical insufficiency and intra-amniotic infection/inflammation, 3 (14%) had microorganisms in the amniotic fluid. Of the 22 patients, 6 (27%) delivered within 1 week of amniocentesis and the remaining 16 (73%) delivered more than 1 week after the diagnostic procedure. Among these, 12 had a repeat amniocentesis to assess the microbial and inflammatory status of the amniotic cavity; in 75% (9/12), there was objective evidence of resolution of intra-amniotic inflammation or intra-amniotic infection demonstrated by analysis of amniotic fluid at the time of the repeat amniocentesis. Of the 4 patients who did not have a follow-up amniocentesis, all delivered ≥34 weeks, 2 of them at term; thus, treatment success occurred in 59% (13/22) of cases. CONCLUSION: In patients with cervical insufficiency and intra-amniotic infection/inflammation, administration of antibiotics (ceftriaxone, clarithromycin, and metronidazole) was followed by resolution of the intra-amniotic inflammatory process or intra-amniotic infection in 75% of patients and was associated with treatment success in about 60% of cases.
引用
- Oh KJ, Romero R, Park JY, et al. Evidence that antibiotic administration is effective in the treatment of a subset of patients with intra-amniotic infection/inflammation presenting with cervical insufficiency. Am J Obstet Gynecol. 2019. PMID: 30928565. doi:10.1016/j.ajog.2019.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。